An interventional study of Home-exercise program in Dysmenorrhea Primary, sponsored by University of Sharjah. Not yet recruiting. Open to female participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by University of Sharjah · Not applicable, Interventional, and Treatment
What is this study about? Dysmenorrhea, commonly known as painful period, is a common gynecological symptom experienced by several women of reproductive age. This particular type of pain arises during the menstrual cycle, often negatively impacting the quality of life and ability to successfully carry out daily activities and academic or work performance. This is study will involve physiotherapy treatment in the form of a home-based exercise program for those experiencing dysmenorrhea. The purpose of this study is to determine how effective this exercise intervention is by assessing the pain score, menstrual symptoms, gait performance and cognitive-motor control.
What will the participant have to do if they take part? They will be asked to come to the University of Sharjah so the investigators can get some measurements. The participant will be asked to fill a form with the basic information about themselves, including as name, age, occupation, height, weight and contact details. They will also be asked about their menstrual pain score on VAS pain scale and to complete a questionnaire about their menstrual symptoms and lifestyle (such as physical activity, sleep, diet etc.). The physiotherapist will then give them a demonstration of the exercises they need to do during this 8-week program. The participant will be required to follow a video recording of the exercises to complete 3 sessions each week, for about 30 minutes. Necessary follow-up will take place each week. They will be given an exercise diary to keep track of when they do these sessions and for how long. On completion of all sessions after 8 weeks, the assessment previously done will be repeated.
What is the criteria for being selected? They study includes females, aged between 18 and 25, who experience dysmenorrhea.
Possible risks of taking part? There are no risks from this study. All the information will be confidential and when the study is finished, they will be destroyed.
Are there any possible benefits? There is expected benefit of the exercises on decreasing menstrual pain and symptoms.
Does the participant have to take part in this study? No. Participation is completely voluntary. If the participant does not wish to consent, they can refuse. If they wish to take part and then change their mind later, they can withdraw from the study any time.
Will the participant's taking part in this study be kept confidential? All the information taken from the participant will remain confidential and only the results will be used in the data analysis with the supervisor without using their name or address so they will not be recognised. At the end of the study, all personal information will be destroyed.
What will happen to the results of the research study? The participant will be notified about the study results once the study has been completed.
430 studies on the registry are indexed under Dysmenorrhea; 107 are open to participants now.
This study's planned enrollment of 86 is above the median of 62 across 363 interventional studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →University of Sharjah is the lead sponsor of 42 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Home-exercise program
Waitlist control group
The participants will then be given a clear explanation of the exercises to be performed as part of the home-based exercise program. They will be provided with a demonstrations video that will guide each session. Each exercise session will last for 30 minutes, 3/week, for 8 weeks. Participants will perform 10 minutes of progressive muscle relaxation exercise, followed by 10 minutes of core exercises, and finally 10 mintes of stretching exercises. They will required to complete an exercise diary. Exercise progressions will be applied across weeks 3-4 and again at weeks 5-6 and 7-8 (e.g., increased hold durations, repetitions, and resistance band progression for core exercises).
Pain intensity
Pain intensity is self-reported on the Visual Analogue Scale for Pain (VAS Pain), which is a continuous scale in the form of a 100mm line, marked by "no pain" (score of 0) on one end and "pain as bad as it could be" (score of 100) on the other end. The participant is required to make a perpendicular line on the VAS scale that they feel best represent their pain intensity. Change in the pain intensity at baseline and after 8 weeks of intervention will be noted.
Time frame: Baseline and 8 weeks
Cortical Silent Period
Cortical silent period (CSP) will be assessed using the transcranial magnetic stimulation (TMS) apparatus. Single-pulse TMS will be administered using a figure-of-eight coil positioned over the primary motor cortex. CSP duration (ms) will be measured from the MEP onset to return of voluntary EMG activity following cortical stimulation. The minimal effective stimulation intensity will be used to ensure participant safety. Changes at baseline and after 8 weeks of intervention will be noted.
Time frame: Baseline and 8 weeks
Dual-Task Gait Performance
Gait performance, including speed, cadence, stride length and double support time, will be assessed comparatively for single-task walking and dual-task walking (during cognitive tasks). Gwalk g-sensors equipment will be used for gait analysis. Changes in parameters as baseline and after 8 weeks intervention will be noted.
Time frame: Baseline and 8 weeks
Dual-Task Cognitive Performance
Cognitive Performance on three tasks (logistic, semantic verbal fluency and working memory) will assessed during walking, at baseline and after 8 weeks intervention.
Time frame: Baseline and 8 weeks
Electroencephalography (EEG) data
Brain activity for cognitive-motor control (Theta/alpha coherence) will be assessed during dual-walking task, using the NeXus-Q32 equipment. Changes in parameters at baseline and after 8 week intervention will be noted.
Time frame: Baseline and 8 weeks
Dysmenorrhea impact
The Working Ability, Location, Intensity, Days of pain, and Dysmenorrhoea (WaLIDD) questionnaire will assess the impact of dysmenorrhoea on work and daily functioning. It measures the severity of dysmenorrhea by a total scoring range of 0 to 12 points, where a higher score indicates greater severity. Changes in total score at baseline and following 8 week intervention will be noted.
Time frame: Baseline and 8 weeks
Menstrual Symptoms and Distress
Menstrual Distress Questionnaire (MEDI-Q) will be used to objectively assess the impact of menstrual pain, physical discomfort, emotional/cognitive changes, and gastrointestinal disturbances, as part of menstrual symptoms experienced in women with primary dysmenorrhea, at baseline and after 8 weeks intervention. The minimum score obtainable is "0", indicating the absence of any specified symptom relevant to generate distress during menstruation in the previous 12 months, and the maximum score is "125", indicating the presence of all the investigated symptoms in more than one-half of menstruations in the past year, each of them generating severe distress. Changes in total score at baseline and following 8 week intervention will be noted.
Time frame: Baseline and 8 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 178 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 6 months is below that.
Counting every sponsor, half of 188 studies reached it within 8 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sharjah